Armata Pharmaceuticals (ARMP) Non-Current Debt (2023 - 2026)

Armata Pharmaceuticals (ARMP) has 4 years of Non-Current Debt data on file, last reported at $88.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt changed N/A year-over-year to $88.0 million; the trailing twelve-month figure through Mar 2026 stood at $88.0 million (changed N/A YoY), and the FY2025 full-year result was $103.1 million, up 357.26% from the prior year.
• Non-Current Debt eased to $88.0 million in Q1 2026, from $103.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $103.1 million in Q4 2025 to a low of $15.2 million in Q3 2025.
• A 4-year average of $44.3 million and a median of $23.7 million in 2023 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt slipped 4.79% in 2024 and surged 357.26% in 2025, its largest moves.
• Tracing ARMP's Non-Current Debt over 4 years: stood at $23.7 million in 2023, then dropped by 4.79% to $22.5 million in 2024, then surged by 357.26% to $103.1 million in 2025, then decreased by 14.64% to $88.0 million in 2026.
• Business Quant data shows ARMP's Non-Current Debt at $88.0 million in Q1 2026, $103.1 million in Q4 2025, and $15.2 million in Q3 2025.